VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Gandara on the Heat Shock Protein 90 Inhibitor Ganetespib

David R. Gandara, MD
Published: Monday, Jul 01, 2013

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.

There are multiple molecular targets for heat shock protein inhibitors, Gandara says, making the new drug class of particular interest. In the GALAXY-1 trial, presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, ganetepib in combination with docetaxel was compared to docetaxel alone for second-line therapy of lung adenocarcinoma. Ganetepib and docetaxel showed benefit compared with docetaxel alone in overall survival, progression-free survival, and overall response rate.

Heat shock protein inhibitors are active in multiple situations: EGFR-mutant cancer, ALK-fusion cancer, and KRAS-mutant cancer. These data, as well as upcoming data, will help propel this class of drugs to approval in the next few years, Gandara says.

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Cancer Center, discusses treatment with the heat shock protein 90 inhibitor ganetespib.

There are multiple molecular targets for heat shock protein inhibitors, Gandara says, making the new drug class of particular interest. In the GALAXY-1 trial, presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, ganetepib in combination with docetaxel was compared to docetaxel alone for second-line therapy of lung adenocarcinoma. Ganetepib and docetaxel showed benefit compared with docetaxel alone in overall survival, progression-free survival, and overall response rate.

Heat shock protein inhibitors are active in multiple situations: EGFR-mutant cancer, ALK-fusion cancer, and KRAS-mutant cancer. These data, as well as upcoming data, will help propel this class of drugs to approval in the next few years, Gandara says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x